M
Monali Desai
Researcher at AbbVie
Publications - 14
Citations - 3327
Monali Desai is an academic researcher from AbbVie. The author has contributed to research in topics: Venetoclax & Internal medicine. The author has an hindex of 7, co-authored 10 publications receiving 2692 citations. Previous affiliations of Monali Desai include Ain Shams University.
Papers
More filters
Journal ArticleDOI
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts,Matthew S. Davids,John M. Pagel,Brad S. Kahl,Soham D. Puvvada,John F. Gerecitano,Thomas J. Kipps,Mary Ann Anderson,Mary Ann Anderson,Jennifer R. Brown,Lori A. Gressick,Shekman Wong,Martin Dunbar,Ming Zhu,Monali Desai,Elisa Cerri,Sari H. Enschede,Rod A. Humerickhouse,William G. Wierda,John F. Seymour,John F. Seymour +20 more
TL;DR: Selective targeting of BCL2 with venetoclax had a manageable safety profile and induced substantial responses in patients with relapsed CLL or SLL, including those with poor prognostic features.
Journal ArticleDOI
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
Stephan Stilgenbauer,Barbara Eichhorst,Johannes Schetelig,Steven Coutre,John F. Seymour,Talha Munir,Soham D. Puvvada,Clemens M. Wendtner,Andrew W. Roberts,Wojciech Jurczak,Stephen P. Mulligan,Sebastian Böttcher,Mehrdad Mobasher,Ming Zhu,Monali Desai,Brenda Chyla,Maria Verdugo,Sari H. Enschede,Elisa Cerri,Rod A. Humerickhouse,Gary Gordon,Michael Hallek,William G. Wierda +22 more
TL;DR: Results of this trial show that venetoclax monotherapy is active and well tolerated in patients with relapsed or refractory del(17p) chronic lymphocytic leukaemia, providing a new therapeutic option for this very poor prognosis population.
Journal ArticleDOI
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids,Andrew W. Roberts,Andrew W. Roberts,John F. Seymour,John F. Seymour,John M. Pagel,Brad S. Kahl,William G. Wierda,Soham D. Puvvada,Thomas J. Kipps,Mary Ann Anderson,Mary Ann Anderson,Ahmed Salem,Ahmed Salem,Martin Dunbar,Ming Zhu,Franklin Peale,Jeremy A. Ross,Lori A. Gressick,Monali Desai,Su Young Kim,Maria Verdugo,Rod A. Humerickhouse,Gary Gordon,John F. Gerecitano +24 more
TL;DR: Selective targeting of BCL-2 with venetoclax was well tolerated, and single-agent activity varied among NHL subtypes, and 1,200 mg was determined to be the recommended single- agent dose for future studies in FL and DLBCL.
Journal ArticleDOI
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
John F. Seymour,John F. Seymour,Shuo Ma,Danielle M. Brander,Michael Y. Choi,Jacqueline C. Barrientos,Matthew S. Davids,Mary Ann Anderson,Mary Ann Anderson,Anne W. Beaven,Steven T. Rosen,Constantine S. Tam,Constantine S. Tam,Betty Prine,Suresh Agarwal,Wijith Munasinghe,Ming Zhu,Leanne Lash,Monali Desai,Elisa Cerri,Maria Verdugo,Su Young Kim,Rod A. Humerickhouse,Gary Gordon,Thomas J. Kipps,Andrew W. Roberts +25 more
TL;DR: The primary outcomes were to assess the safety profile, to determine the maximum tolerated dose, and to establish the recommended phase 2 dose of venetoclax when given in combination with rituximab.
Journal ArticleDOI
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.
Stephan Stilgenbauer,Barbara Eichhorst,Johannes Schetelig,Peter Hillmen,John F. Seymour,Steven Coutre,Wojciech Jurczak,Stephen P. Mulligan,Anna Schuh,Sarit Assouline,Clemens-Martin Wendtner,Andrew W. Roberts,Matthew S. Davids,Johannes Bloehdorn,Talha Munir,Sebastian Böttcher,Lang Zhou,Ahmed Salem,Monali Desai,Brenda Chyla,Jennifer Arzt,Su Young Kim,Maria Verdugo,Gary S. Gordon,Michael Hallek,William G. Wierda +25 more
TL;DR: Venetoclax achieves durable responses and was well tolerated in patients with 17p deleted relapsed/refractory chronic lymphocytic leukemia and a high rate of blood MRD < 10-4 was achieved in this high-risk population.